m108
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 11, 2021 (NCT04894825)
Timeline
Indications
Mechanism of action
- Cadherin-1ANTAGONIST
CDH1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06177041 | Phase 3 | Dec 18, 2023 | FutureGen Biopharmaceutical (Beijing) Co., Ltd |
| NCT04894825 | Phase 1 | Jun 11, 2021 | FutureGen Biopharmaceutical (Beijing) Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| FutureGen Biopharmaceutical (Beijing) Co., Ltd | For profit | 2 | 2 | 2 | 2021 |
1 organizations
Page 1 / 1